19 August 2013
Irribow OD Tablet is a drug for treating IBS-D developed using WOWTAB which is one of the Astellas’ proprietary drug delivery technologies.
Singapore: Astellas Pharma has obtained the marketing approval of Irribow OD 1 Tablets 2.5µg / 5µg (generic name: ramosetron hydrochloride) in Japan. They were approved for an additional formulation of Irribow Tablets with the indication of diarrhea-predominant irritable bowel syndrome (IBS-D ) in male.
Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”. In India it is marketed under the brand name of“IBset”.
It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the tradename Iribo (イリボー).  Elsewhere it is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) 
- Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). “Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery”.Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043.PMID 10648342.
- Summary in Japanese. Retrieved on September 4, 2012.
- Abridged prescribing information – Nasea (MIMS Philippines). Retrieved on June 13, 2008.